Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 26,000,000
Countries
Sector(s)
Cyprus : € 26,000,000
Health : € 5,200,000
Services : € 20,800,000
Signature date(s)
1/06/2017 : € 5,200,000
1/06/2017 : € 20,800,000

Summary sheet

Release date
15 April 2016
Status
Reference
Signed | 01/06/2017
20160037
Project name
Promoter - financial intermediary
CYPRUS INSTITUTE FOR NEUROLOGY AND GENETICS R&D
THE CYPRUS FOUNDATION FOR MUSCULAR DYSTROPHY RESEARCH
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 21 million
EUR 31 million
Location
Sector(s)
Description
Objectives

The project includes construction of an extension and purchase of equipment as well as the intangible cost of research activities at the Cyprus Institute of Neurology and Genetics.

The purpose of the project is to enhance the services, research and academic activities performed at the Cyprus Institute of Neurology and Genetics. The EIB will mainly support investments in new research and development (R&D) infrastructure as well as research programmes. The project is fully consistent with the Bank's Knowledge Economy objectives and the targets agreed in the context of the EU Horizon 2020.

Environmental aspects
Procurement

Hospitals and medical research institutes are not specifically mentioned in the Environmental Impact Assessment (EIA) Directive 2011/92/EU as amended, though the project is covered by Annex II of the directive in relation to urban development. The Bank's services will verify during appraisal whether an EIA is required by the competent authority.

The Bank will require the promoter to ensure that contracts for the implementation of the project have been/shall be tendered in accordance with the relevant applicable EU procurement legislation (Directives 2004/18/EC or 2014/24/EU where applicable, and/or 2004/17/EC, or 2014/25/EU where applicable, as well as Directives 89/665/EEC and 92/13/EEC) as interpreted by the Court of Justice of the EU, with publication of tender notices in the Official Journal of the EU, as and where required.

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

Documents

Environmental and Social Data Sheet (ESDS) - CYPRUS INSTITUTE FOR NEUROLOGY AND GENETICS R&D
Publication Date
24 Dec 2016
Document language
Main Topic
Lending
Document Number
67162431
Document Focus
Environmental Information
Project Number
20160037
Sector(s)
Regions
Countries
Publicly available
Download now

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

Related publications